Four Deaths Prompt FDA Safety Concerns About Novel Schizophrenia Drug
(MedPage Today) -- The FDA flagged a potential safety signal after four deaths were reported among patients with treatment-resistant schizophrenia who received investigational evenamide in clinical trials, Newron Pharmaceuticals said Thursday...
We haven't written up this one. MedPage Today has the full story — the link below goes straight to it.